I agree with Respert, buttoning down the CRC protocol has taken time but it must be tight…now we know it’s coming even if it was not yesterday. A reminder the next catalyst will appear BEFORE the CRC study start, and it is likely to portend a seismic change in share price long before and CRC results would be filed. It is useful to take another look at the pipeline page just updated. For the uninitiated who may visit it from a PR as we received today there are several things that stand out after a quick glance:

1) Wow, what a broad suite of indications…cancer…multiple types!
2) Inflammation…again, multiple origins? Strong hints of platform molecule. Alzheimer’s!
3) Multiple trials already phase 2 and a successful trial from phase 3?!
4) Leronlimab to PREVENT AND/OR REVERSE liver inflammation. Preclinical, but the MASH mice, those still squeaking at the end of the study this September under the influence of Leronlimab have the potential to catapult direct to phase 2 under a partnership. If so, current share prices should be in the rear-view mirror. Remind yourself Cytodyn has already completed a phase 2 study for MASH in humans…this is a very high probability event IMHO. While preclinical I expect this study will kick it in like Hocker did to win gold in Olympic record time to astonish the front runners in the men’s 1500 meter run.

Marketing 101 puts your cherished jewel first…Cytodyn is going after cancer in a big way. I am reminded of Scott Kelly’s comment: “I think we will be known as an oncology company.”

Cancer lanes in blue, inflammation in red…mix them together and you have purple…Tyrolian purple dye was the most cherished and expensive in the ancient world, reserved strictly for royal wealth and privilege. In due course Leronlimab will be clothed in the same awe.